{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T05:03:17Z","timestamp":1680757397029},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00393-022-01312-3","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T22:07:23Z","timestamp":1674511643000},"page":"195-205","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DMARD-Therapie und Hautkrebs","DMARD treatment and skin cancer"],"prefix":"10.1007","volume":"82","author":[{"given":"Katharina","family":"Drerup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Sophie","family":"Bohne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"Gl\u00e4ser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"issue":"9","key":"1312_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1001\/jamadermatol.2015.1188","volume":"151","author":"MM Asgari","year":"2015","unstructured":"Asgari\u00a0MM et al (2015) Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998\u20132012. JAMA Dermatol 151(9):976\u2013981","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1312_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1940-6207.CAPR-09-0096","volume":"3","author":"HH Bailey","year":"2010","unstructured":"Bailey\u00a0HH et al (2010) A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res 3(1):35\u201347","journal-title":"Cancer Prev Res"},{"issue":"8","key":"1312_CR3","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","volume":"13","author":"JN Bavinck","year":"1995","unstructured":"Bavinck\u00a0JN et al (1995) Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a\u00a0double-blind, placebo-controlled study. J\u00a0Clin Oncol 13(8):1933\u20131938","journal-title":"J Clin Oncol"},{"issue":"04","key":"1312_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1055\/a-1487-3992","volume":"48","author":"A-S Bohne","year":"2022","unstructured":"Bohne\u00a0A\u2011S, K\u00e4hler\u00a0KC (2022) Update aktinische Keratosen \u2013 Neuigkeiten und Relevanz f\u00fcr den Alltag. Aktuelle Derm 48(04):141\u2013144","journal-title":"Aktuelle Derm"},{"issue":"9","key":"1312_CR5","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","volume":"59","author":"S De Germay","year":"2020","unstructured":"De Germay\u00a0S et al (2020) Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology 59(9):2360\u20132367","journal-title":"Rheumatology"},{"issue":"1","key":"1312_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biomedicines6010006","volume":"6","author":"D Didona","year":"2018","unstructured":"Didona\u00a0D, Paolino\u00a0G, Bottoni\u00a0U, Cantisani\u00a0C (2018) Non melanoma skin cancer pathogenesis overview. Biomedicines 6(1):6","journal-title":"Biomedicines"},{"issue":"6","key":"1312_CR7","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.3390\/ijms140612222","volume":"14","author":"J D\u2019Orazio","year":"2013","unstructured":"D\u2019Orazio\u00a0J, Jarrett\u00a0S, Amaro-Ortiz\u00a0A, Scott\u00a0T (2013) UV radiation and the skin. Int J Mol Sci 14(6):12222\u201312248","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1312_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","volume":"156","author":"S Esse","year":"2020","unstructured":"Esse\u00a0S, Mason\u00a0KJ, Green\u00a0AC, Warren\u00a0RB (2020) Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis. JAMA Dermatol 156(7):787\u2013794","journal-title":"JAMA Dermatol"},{"key":"1312_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2021.04.029","volume":"152","author":"C Garbe","year":"2021","unstructured":"Garbe\u00a0C et\u00a0al (2021) Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943\u20132036. Eur J Cancer 152:18\u201325","journal-title":"Eur J Cancer"},{"issue":"1","key":"1312_CR10","first-page":"adv00365","volume":"101","author":"F Giannopoulos","year":"2021","unstructured":"Giannopoulos\u00a0F et al (2021) Methotrexate use for patients with psoriasis and risk of cutaneous squamous cell carcinoma: A nested case-control study. Acta Derm Venereol 101(1):adv365","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1312_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11864-020-00815-y","volume":"22","author":"CS Greif","year":"2021","unstructured":"Greif\u00a0CS, Srivastava\u00a0D, Nijhawan\u00a0RI (2021) Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol 22(2):11","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"1312_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/CMR.0b013e32831bc44a","volume":"19","author":"E Guenova","year":"2009","unstructured":"Guenova\u00a0E et\u00a0al (2009) Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res 19(4):271\u2013273","journal-title":"Melanoma Res"},{"issue":"2","key":"1312_CR13","first-page":"214","volume":"17","author":"BM Lang","year":"2019","unstructured":"Lang\u00a0BM et al (2019) S2k-Leitlinie Basalzellkarzinom der Haut \u2013 Teil 2: Therapie, Pr\u00e4vention und Nachsorge. J\u00a0Dtsch Dermatol Ges 17(2):214\u2013231","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"1312_CR14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12935-021-02325-9","volume":"21","author":"R Liu","year":"2021","unstructured":"Liu\u00a0R, Wan\u00a0Q, Zhao\u00a0R, Xiao\u00a0H, Cen\u00a0Y, Xu\u00a0X (2021) Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a\u00a0systemic review and meta-analysis. Cancer Cell Int 21(1):614","journal-title":"Cancer Cell Int"},{"issue":"5","key":"1312_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/fon-2020-0823","volume":"17","author":"S Keeping","year":"2021","unstructured":"Keeping\u00a0S et\u00a0al (2021) Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Future Oncol 17(5):611\u2013627","journal-title":"Future Oncol"},{"issue":"2","key":"1312_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer\u00a0LK et\u00a0al (2017) Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a\u00a0collaborative project of 11 European biologic registers. Ann Rheum Dis 76(2):386\u2013391","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1312_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/ced.13244","volume":"42","author":"L Nestor","year":"2017","unstructured":"Nestor\u00a0L et\u00a0al (2017) Nicotinamide for prevention of nonmelanoma skin cancers: a\u00a0change in practice? Clin Exp Dermatol 42(8):945\u2013946","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1312_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","volume":"78","author":"SA Pedersen","year":"2018","unstructured":"Pedersen\u00a0SA et al (2018) Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J\u00a0Am Acad Dermatol 78(4):673\u2013681.e9","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1312_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjd.18887","volume":"183","author":"S Polesie","year":"2020","unstructured":"Polesie\u00a0S, Gillstedt\u00a0M, Paoli\u00a0J, Osmancevic\u00a0A (2020) Methotrexate treatment for patients with psoriasis and risk of cutaneous melanoma: a\u00a0nested case\u2013control study. Br J Dermatol 183(4):684\u2013691","journal-title":"Br J Dermatol"},{"issue":"2","key":"1312_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","volume":"152","author":"FI Scott","year":"2016","unstructured":"Scott\u00a0FI et\u00a0al (2016) Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a\u00a0history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 152(2):164\u2013172","journal-title":"JAMA Dermatol"},{"key":"1312_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3687","author":"R Seror","year":"2019","unstructured":"Seror\u00a0R et\u00a0al (2019) Risk of malignancies across biologic classes in rheumatoid arthritis: analysis of a\u00a0national claim database. Arthritis Rheumatol. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3687","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1312_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon\u00a0DH et al (2020) Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med 172(6):369\u2013380","journal-title":"Ann Intern Med"},{"key":"1312_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel\u00a0S et\u00a0al (2017) Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2013update 2017. Eur J Cancer 83:247\u2013257","journal-title":"Eur J Cancer"},{"issue":"6","key":"1312_CR24","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE Van Daalen","year":"2017","unstructured":"Van Daalen\u00a0EE et al (2017) Effect of rituximab on malignancy risk in patients with ANCA-Associated vasculitis. Ann Rheum Dis 76(6):1064\u20131069","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1312_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jdv.12041","volume":"28","author":"JMPA Van Den Reek","year":"2014","unstructured":"Van Den Reek\u00a0JMPA et al (2014) Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J\u00a0Eur Acad Dermatology Venereol 28(1):27\u201333","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"4","key":"1312_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop\u00a0KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13(4):234\u2013243","journal-title":"Nat Rev Rheumatol"},{"key":"1312_CR27","unstructured":"https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Melanom\/melanom_node.html;. Zugegriffen: 4. Okt. 2022"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01312-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T16:32:17Z","timestamp":1680712337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01312-3"}},"subtitle":["Erkennen, Stand des Wissens und Pr\u00e4vention","Recognition, state of knowledge and prevention"],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01312-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"19 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Drerup hat als Beraterin und\/oder Referentin und\/oder Pr\u00fcfarzt in klinischen Studien mit folgenden Firmen ohne Bezug zum eingereichten Beitrag kooperiert: AbbVie, Almirall-Hermal, Lilly, Leo Pharma, Novartis und UCB Pharma. A.-S.\u00a0Bohne hat Reisekostenunterst\u00fctzungen von Sun Pharma, Pierre-Fabre und Bristol-Myers Squibb ohne Bezug zu dem eingereichten Beitrag erhalten. R.\u00a0Gl\u00e4ser hat Vortragshonorare von AbbVie, INFECTOPHARM Arzneimittel, Janssen-Cilag, Novartis und UCB Pharma ohne Bezug zu dem eingereichten Beitrag erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}